Watch for the full I CAN Phase III eGFR data at week 106, which will determine whether accelerated approval converts to traditional approval and could significantly expand the addressable IgAN population. Also monitor the ASN Kidney Week presentation on 23 October 2026 for additional subgroup data.
Price Chart
Executive Summary
AstraZeneca announced that the FDA granted accelerated approval for Ultomiris (ravulizumab) to reduce proteinuria in adults with primary IgA nephropathy (IgAN), based on a prespecified interim analysis of the I CAN Phase III trial showing a 43.4% placebo-adjusted reduction in proteinuria at 34 weeks. This is the fifth approved indication for Ultomiris and the first C5 complement inhibitor approved in IgAN, expanding the drug's addressable patient population in a rare disease affecting over 200,000 people in the US.
Key Facts
- Ultomiris received accelerated FDA approval for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression.
- Approval based on prespecified interim analysis of Phase III I CAN trial showing 43.4% placebo-adjusted reduction in proteinuria (UPCR) at 34 weeks (p<0.0001).
- This is the fifth approved indication for Ultomiris, adding to PNH, aHUS, gMG, and NMOSD.
- IgAN affects more than 200,000 people in the US; approximately half with elevated proteinuria or reduced kidney function are at high risk of progression to kidney failure within 10 years.
- Continued approval is contingent on verification of clinical benefit in the ongoing I CAN trial (eGFR endpoint at week 106).
- Regulatory submissions based on interim results are under review in Japan and additional countries.
- Late-breaking results from I CAN will be presented at ASN Kidney Week on 23 October 2026.
Financial Impact
Expands Ultomiris addressable market by adding a rare kidney disease with >200,000 US patients; revenue contribution not disclosed but represents a meaningful new indication for a blockbuster drug.
Risk Factors
- Accelerated approval is contingent on confirming clinical benefit (eGFR endpoint) in the ongoing I CAN trial; failure to show kidney function preservation could limit or reverse approval.
- Competition from other IgAN therapies (e.g., Tarpeyo, sparsentan) may limit market penetration.
- Ultomiris is administered intravenously every 8 weeks, which may be less convenient than oral alternatives for some patients.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009093 |
| Document: 0001654954-26-009093-index-headers.html | 0001654954-26-009093 |
| Document: 0001654954-26-009093-index.html | 0001654954-26-009093 |
| Document: 0001654954-26-009093.txt | 0001654954-26-009093 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $171.54 | awaiting T+1 | — | $171.15 (−0.23%) |
Oct 22, 2026 5d ago | 6-K | $172.57 $171.49 | ▼ −0.63% | ▼ −0.10% | $171.15 (−0.82%) |
Oct 15, 2026 12d ago | Court Ruling | $165.41 $163.95 | ▼ −0.88% | ▼ −1.31% | $171.15 (+3.47%) |
Oct 5, 2026 22d ago | 6-K | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $171.15 (+9.34%) |
Oct 2, 2026 25d ago | 6-K | $156.90 $156.53 | ▼ −0.24% | ▼ −0.91% | $171.15 (+9.08%) |
Oct 2, 2026 25d ago | Court Ruling | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $171.15 (+9.34%) |
Oct 1, 2026 26d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $171.15 (+8.53%) |
Oct 1, 2026 26d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $171.15 (+8.53%) |
Sep 29, 2026 28d ago | 6-K | $164.21 $161.47 | ▼ −1.67% | ▼ −1.46% | $171.15 (+4.23%) |
Sep 23, 2026 4w ago | 6-K | $163.33 $164.56 | ▲ +0.75% | ▲ +0.84% | $171.15 (+4.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers